Literature DB >> 34736804

An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration.

Aureliano Paolo Finch1, Michela Meregaglia2, Oriana Ciani2, Bram Roudijk3, Claudio Jommi2.   

Abstract

OBJECTIVES: To test the feasibility of using videoconferencing (VC) administered interviews and to derive an EQ-5D-5L value set for Italy.
METHODS: Preferences were collected using the EuroQol standardized valuation protocol (EQ-VT) administered via VC. Two valuation methods were employed, composite time trade-off (cTTO) and discrete choice experiment (DCE). Technical, organizational and protocol feasibility were tested in a pilot of 198 interviews. Upon positive assessment, data collection continued with a target sample of 1000-1200 participants including the pilot. Quality control (QC) procedures were employed to monitor interviewers' performance during the pilot and the data collection. Data were modelled using GLS, Tobit, Logit and Hybrid models with different error specifications. Monotonicity of coefficients, statistical significance, and theoretical considerations informed the model choice.
RESULTS: Dropouts and technical problems occurred in less than 5% of the 198 pilot interviews. Protocol compliance was demonstrated with significant improvements in QC parameters and limited interviewers' effects, for all interviewers. Overall, interviewers were satisfied with this mode of administration, highlighting it allows flexibility and efficient scheduling. Based on these results, VC was deemed as a feasible mode of administration. The study collected preferences for 1182 responders, including the pilot interviews. The demographic characteristics of the sample were representative of the Italian general population for age, gender and geographical macro-areas. The hybrid Tobit heteroscedastic model without constant estimated on the full sample (including pilot) was selected for the derivation of the value set. Values ranged from -0.571 for the worst health state (55555) to 1 for the best health state (11111). Pain/discomfort registered the largest decrement, followed by mobility, anxiety/depression, self-care, and usual activities. 523 health states were worse than dead.
CONCLUSIONS: VC is viable for the conduct of valuation interviews. The Italian value set for the EQ-5D-5L can be used for value determinations of health technologies.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  EQ-5D-5L; Feasibility; Mode of administration; Preferences; Valuation study; Video-telephony; Videoconferencing; cTTO

Mesh:

Year:  2021        PMID: 34736804     DOI: 10.1016/j.socscimed.2021.114519

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  5 in total

1.  A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets.

Authors:  Donna Rowen; Clara Mukuria; Emily McDool
Journal:  Pharmacoeconomics       Date:  2022-07-13       Impact factor: 4.558

2.  Exploring the Comparability of Face-to-Face Versus Video Conference-Based Composite Time Trade-Off Interviews: Insights from EQ-5D-Y-3L Valuation Studies in Belgium and Spain.

Authors:  Anabel Estévez-Carrillo; Sarah Dewilde; Mark Oppe; Juan M Ramos-Goñi
Journal:  Patient       Date:  2022-02-16       Impact factor: 3.481

3.  Anal Fistula Human Amniotic Membrane Endosealing (F-HAME): A Proof of Concept Study.

Authors:  Ugo Grossi; Maurizio Romano; Serena Rossi; Gaetano Gallo; Arcangelo Picciariello; Carla Felice; Diletta Trojan; Giulia Montagner; Giacomo Zanus
Journal:  Front Surg       Date:  2022-03-28

4.  A Value Set for the EQ-5D-Y-3L in the Netherlands.

Authors:  Bram Roudijk; Ayesha Sajjad; Brigitte Essers; Stefan Lipman; Peep Stalmeier; Aureliano Paolo Finch
Journal:  Pharmacoeconomics       Date:  2022-10-10       Impact factor: 4.558

5.  Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments.

Authors:  Agata Łaszewska; Ayesha Sajjad; Jan Busschbach; Judit Simon; Leona Hakkaart-van Roijen
Journal:  Pharmacoeconomics       Date:  2022-10-06       Impact factor: 4.558

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.